Under construction – not a live service
Sign in
Taking people in FranceNo phase

Endurance Training Program for People With Sickle Cell Disease

Tests an endurance training program in people with sickle cell disease aged 15 or older.

Plain-language title generated from the registry record
Registry title: Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life.

Key facts

Where
Créteil, FranceSee the site

Where in France

  • Henri Mondor HospitalCréteil, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Assistance Publique - Hôpitaux de Paris
Trial code
NCT06823219
Record updated
12 February 2025
Original description
Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Due to anaemia and multiple pulmonary, cardiac, endothelial, muscle, and metabolic dysfunctions, fatigue and poor physical capacity are common in SCD patients and constitute the primary reason for a sedentary lifestyle.Read full original descriptionShow less

Evaluation of a Long-term Endurance Training Program in Patients With Sickle Cell Disease: Benefits on Clinical Profile, Physical Fitness and Quality of Life of Patients

Sickle cell disease (SCD), the most common genetic disease worldwide and in France, is an inherited haemoglobinopathy characterised by chronic haemolytic anaemia, vaso-occlusive crisis (VOC), acute pain, and multi-organ damage. Due to anaemia and multiple pulmonary, cardiac, endothelial, muscle, and metabolic dysfunctions, fatigue and poor physical capacity are common in SCD patients and constitute the primary reason for a sedentary lifestyle.

However, recent findings demonstrated in the first randomised, controlled, and prospective study implementing endurance training in SCD that, when adequately calibrated, regular moderate-intensity endurance training is not only safe but also beneficial for patients (primary outcome: improvement of physical ability).

This pivotal randomised, controlled, prospective study is designed to prove, on a large multicentre cohort, adult and paediatric, including patients with complications and over a longer period (one year).

The objective of the study is to demonstrate the efficacy of participating in a program of regular physical activity to reduce the rate of vaso-occlusive crises requiring hospitalisation and to improve physical ability in patients with SCD.

Inclusion: Aged over 15 years and 3 months; Male or female; Patients with sickle cell disease (HbSS or HbS-βthal0); Affiliated to a social security system; Having freely given their written consent after having been informed of the purpose, the procedure and the potential risks involved; Patients in stabilised condition at the start of the experiment: at least 1 month after an acute chronic event or at least 3 months after a blood transfusion; Patients hospitalised for vaso-occlusive crisis at least once in the last 3 years.

Exclusion: Patients with an intercurrent condition unresolved for less than a month; Patients hospitalised for cardiac decompensation during the last 12 months; Patients unable to understand the objectives and conditions of the study and unable to give cons; Patient whose adherence to the protocol is unlikely according to the investigator; Patients who already partake in regular physical activity (more than 1 hour of moderate-intensity physical activity per week); Patients with a chronic inflammatory and/or infectious pathology; Patients on anticoagulant treatment or with a pacemaker/defibrillator; Pregnant patients / breastfeeding woman; Patients deprived of liberty by judicial or administrative decision or patient under guardianship.

ClinicalTrials.gov NCT06823219